

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

| APPLICATION NO.  | FILING DATE     | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO.     | CONFIRMATION NO. |
|--|-----------------|----------------------|-------------------------|------------------|
| 09/975,502   | 10/11/2001      | Jerry G. Henslee     | 5972.US.P7 1118         |                  |
| 23492  | 7590 03/03/2003 |                      |                         |                  |
| STEVEN F. WEINSTOCK ABBOTT LABORATORIES 100 ABBOTT PARK ROAD |                 |                      | EXAMINER                |                  |
|  |                 |                      | HARRIS, ALANA M         |                  |
| DEPT. 377/AP6A<br>ABBOTT PARK, IL 60064-6008                 |                 |                      | ART UNIT PAPER NUMBE    |                  |
|  | , 12            |                      | 1642                    |                  |
|  |                 |                      | DATE MAILED: 03/03/2003 | 14               |

Please find below and/or attached an Office communication concerning this application or proceeding.

| -   |   | Application No.                     | Applicant(s)                   |  |  |  |  |
|---|---|-------------------------------------|--------------------------------|--|--|--|--|
| Office Action Summary   |   | 09/975,502                          | HENSLEE ET AL.                 |  |  |  |  |
|   |   | Examiner                            | Art Unit                       |  |  |  |  |
| -   |   | Alana M. Harris, Ph.D.              | 1642                           |  |  |  |  |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply  |   |                                     |                                |  |  |  |  |
| A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). |   |                                     |                                |  |  |  |  |
| Status<br>1)□   | Responsive to communication(s) filed on   |                                     |                                |  |  |  |  |
| 2a)☐  | .,  | —·<br>is action is non-final.       |                                |  |  |  |  |
| · <u> </u>  | ,   |                                     | rosecution as to the merits is |  |  |  |  |
| 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. <b>Disposition of Claims</b>   |   |                                     |                                |  |  |  |  |
| 4)⊠ Claim(s) 1-5 is/are pending in the application.   |   |                                     |                                |  |  |  |  |
| 4a) Of the above claim(s) is/are withdrawn from consideration.  |   |                                     |                                |  |  |  |  |
|   | i) Claim(s) is/are allowed.   |                                     |                                |  |  |  |  |
| 6) Claim(s) is/are rejected.  |   |                                     |                                |  |  |  |  |
| · -   | 7) Claim(s) is/are objected to.   |                                     |                                |  |  |  |  |
| 8)🖂   | Claim(s) <u>1-5</u> are subject to restriction and/or el  | ection requirement.                 |                                |  |  |  |  |
| Applicati   | on Papers   |                                     |                                |  |  |  |  |
| 9)☐ The specification is objected to by the Examiner.   |   |                                     |                                |  |  |  |  |
| 10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.   |   |                                     |                                |  |  |  |  |
|   | Applicant may not request that any objection to the   | e drawing(s) be held in abeyance. S | see 37 CFR 1.85(a).            |  |  |  |  |
| 11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.   |   |                                     |                                |  |  |  |  |
| If approved, corrected drawings are required in reply to this Office action.  |   |                                     |                                |  |  |  |  |
| 12)☐ The oath or declaration is objected to by the Examiner.  |   |                                     |                                |  |  |  |  |
| Priority under 35 U.S.C. §§ 119 and 120   |   |                                     |                                |  |  |  |  |
| 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).   |   |                                     |                                |  |  |  |  |
| a) ☐ All b) ☐ Some * c) ☐ None of:  |   |                                     |                                |  |  |  |  |
| 1. Certified copies of the priority documents have been received.   |   |                                     |                                |  |  |  |  |
| 2. Certified copies of the priority documents have been received in Application No  |   |                                     |                                |  |  |  |  |
| <ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>   |   |                                     |                                |  |  |  |  |
| 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  |   |                                     |                                |  |  |  |  |
| a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.   |   |                                     |                                |  |  |  |  |
| Attachment(s)   |   |                                     |                                |  |  |  |  |
| 1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413) Paper No(s)   |   |                                     |                                |  |  |  |  |
| 2) Notice   | e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) | 5) Notice of Informal               | Patent Application (PTO-152)   |  |  |  |  |

Application/Control Number: 09/975,502

antigen/antibody complexes.

Art Unit: 1642

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1, 2 and 5, drawn to an assay to detect breast cancer, classified in class 435, subclass 7.1. Claim 1 will be examined with Group I to the extent the assay reads on contacting a test sample with at least two polypeptides.
  - II. Claims 1, 3 and 4, drawn to a method of detecting and diagnosing breast cancer, classified in class 436, subclass 536. Claim 1 will be examined with Group II to the extent assay reads on contacting a test sample with at least two antibodies.
- 2. The inventions are distinct, each from the other because of the following reasons: Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions involve the use of various reagents, implement distinct method steps and yield different endpoints. The assay of Group I correlates the

presence of one or more polypeptides, whereas the assay of Group II detects

Application/Control Number: 09/975,502

Art Unit: 1642

3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

4. A telephone call was made to Cheryl Becker on March 1, 2003 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

- 5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alana M. Harris, Ph.D. whose telephone number is (703) 306-5880. The examiner can normally be reached on 6:30 am to 4:00 pm, with alternate Fridays off.

Page 4

Application/Control Number: 09/975,502

Art Unit: 1642

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, Ph.D. can be reached on (703) 308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4315 for regular communications and (703) 308-4315 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703)308-0196.

ALANA HARRIS PATENT EXAMINER

Alana M. Harris, Ph.D.

March 1, 2003.

Continuation of Attachment(s) 6). Other: Restriction Election Facsimile Transmission.